Intercept looks for redemption in Nash in the third quarter, while Kymera, Zealand and Anavex hope for share price boosts.
Key upcoming clinical results approach in the third quarter for lecanemab, high-dose Eylea and Zimura.
GSK takes on arthritis and Roche aims for convenience, while Pfizer is set to report infant pneumococcal vaccine data.
Pivotal data will show whether KarXT can walk the risk-benefit tightrope.
But a surprise adcom for omecamtiv mecarbil might put a spanner in the works.
Updated data with exa-cel in sickle cell disease and beta-thalassaemia could put the fear into competitors.